|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...1314151617181920212223...6768» |
- warfarin / Generic mfg.
Enrollment open, Trial primary completion date: Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin (clinicaltrials.gov) - Mar 21, 2016
P1/2, N=40, Recruiting, Sponsor: McMaster University
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2015 --> Nov 2016
- melphalan / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Mar 19, 2016
P2, N=16, Completed, Sponsor: Boston Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2015 --> Nov 2016 Active, not recruiting --> Completed | N=35 --> 16 | Trial primary completion date: Jul 2016 --> May 2015
- || dexamethasone / Generic mfg., bendamustine / Generic mfg., pomalidomide / Generic mfg.
Clinical: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (clinicaltrials.gov) - Mar 18, 2016
P1/2, N=56, Recruiting, Sponsor: Cristina Gasparetto
Active, not recruiting --> Completed | N=35 --> 16 | Trial primary completion date: Jul 2016 --> May 2015 Trial primary completion date: Jan 2016 --> Jun 2016
- Enrollment change, Trial primary completion date, Metastases: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (clinicaltrials.gov) - Mar 18, 2016
P1, N=44, Active, not recruiting, Sponsor: Craig Hofmeister
Trial primary completion date: Jan 2016 --> Jun 2016 N=60 --> 44 | Trial primary completion date: Dec 2015 --> Oct 2014
- prednisone / Generic mfg., melphalan / Generic mfg., carfilzomib / Generic mfg.
Clinical: Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) (clinicaltrials.gov) - Mar 18, 2016
P1/2, N=72, Completed, Sponsor: Nantes University Hospital
N=60 --> 44 | Trial primary completion date: Dec 2015 --> Oct 2014 Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Feb 2014
- New trial: Obstructive Sleep Apnoea in Children and Adolescents With Ehlers-Danlos Syndrome (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=50, Not yet recruiting, Sponsor: University of Zurich
- || lenalidomide / Generic mfg., sirolimus / Generic mfg.
Trial primary completion date: Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) (clinicaltrials.gov) - Mar 16, 2016
P1/2, N=53, Active, not recruiting, Sponsor: Sherif S. Farag
Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Feb 2014 Trial primary completion date: Dec 2015 --> Dec 2016
- | ulocuplumab (BMS-936564) / BMS
Trial completion, Enrollment change, Combination therapy: Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 16, 2016
P1, N=46, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | N=64 --> 46
- fenofibrate / Generic mfg.
Enrollment closed: Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma (clinicaltrials.gov) - Mar 15, 2016
P2, N=30, Active, not recruiting, Sponsor: University of Miami
Active, not recruiting --> Completed | N=64 --> 46 Recruiting --> Active, not recruiting
- ||| Trial completion, Trial primary completion date: A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care (clinicaltrials.gov) - Mar 14, 2016
P=N/A, N=1658, Completed, Sponsor: Swedish Orphan Biovitrum
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2015
- bortezomib / Generic mfg., melphalan / Generic mfg., carfilzomib / Generic mfg.
Clinical: Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments (clinicaltrials.gov) - Mar 10, 2016
P1/2, N=45, Active, not recruiting, Sponsor: Oncotherapeutics
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2015 Trial primary completion date: Sep 2015 --> Dec 2016
- bortezomib / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens (clinicaltrials.gov) - Mar 10, 2016
P2, N=5, Terminated, Sponsor: Oncotherapeutics
Trial primary completion date: Sep 2015 --> Dec 2016 N=52 --> 5 | Recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Oct 2015; Terminated by Sponsor of this study.
- ||| bortezomib / Generic mfg., thalidomide / Generic mfg.
Trial completion, Trial primary completion date: Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=110, Completed, Sponsor: Oncotherapeutics
N=52 --> 5 | Recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Oct 2015; Terminated by Sponsor of this study. Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Aug 2015
- ||| Trial completion: Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=164, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Aug 2015 Recruiting --> Completed
- siplizumab (TCD601) / ITBMed
Enrollment change, Trial termination: Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov) - Mar 9, 2016
P2, N=14, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Completed N=30 --> 14 | Suspended --> Terminated; Expiration of MEDI-507
- ||||||| bortezomib / Generic mfg.
Trial completion: OPTIMRETREAT: Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (clinicaltrials.gov) - Mar 9, 2016
P3, N=80, Completed, Sponsor: Janssen-Cilag International NV
N=30 --> 14 | Suspended --> Terminated; Expiration of MEDI-507 Active, not recruiting --> Completed
- Willfact (human von Willebrand factor) / LFB Biotechnologies
Trial primary completion date: Willebrand International Non-interventional Global Surveillance (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=80, Recruiting, Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Jun 2017
- |||| Trial primary completion date, Metastases: Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma (clinicaltrials.gov) - Mar 8, 2016
P3, N=60, Recruiting, Sponsor: InSightec
Trial primary completion date: Dec 2018 --> Jun 2017 Trial primary completion date: Jan 2013 --> Jan 2018
- bazlitoran (IMO-8400) / Idera
Trial primary completion date: Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 (clinicaltrials.gov) - Mar 8, 2016
P1/2, N=24, Enrolling by invitation, Sponsor: Idera Pharmaceuticals, Inc.
Trial primary completion date: Jan 2013 --> Jan 2018 Trial primary completion date: Feb 2016 --> Dec 2016
- Campath (alemtuzumab) / Sanofi
Trial completion, Enrollment change: Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors (clinicaltrials.gov) - Mar 5, 2016
P2, N=2, Completed, Sponsor: University of Arizona
Trial primary completion date: Feb 2016 --> Dec 2016 Recruiting --> Completed | N=60 --> 2
- || Xyntha (moroctocog alfa) / Pfizer
Enrollment change: Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO (clinicaltrials.gov) - Mar 5, 2016
P=N/A, N=120, Recruiting, Sponsor: Pfizer
Recruiting --> Completed | N=60 --> 2 N=200 --> 120
- New P4 trial, HEOR, Cost effectiveness: Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A (clinicaltrials.gov) - Mar 4, 2016
P4, N=20, Completed, Sponsor: Hampshire Hospitals NHS Foundation Trust
- ||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion: Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Feb 27, 2016
P3, N=313, Completed, Sponsor: Amgen
N=200 --> 120 Enrolling by invitation --> Completed
- | Trial completion: Monitoring Trends in Venous Thromboembolism (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=0, Completed, Sponsor: University of Massachusetts, Worcester
Enrolling by invitation --> Completed No longer recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy, Metastases: Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) (clinicaltrials.gov) - Feb 27, 2016
P1, N=34, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Metastases: Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates (clinicaltrials.gov) - Feb 27, 2016
P2, N=111, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | talmapimod (SCIO-469) / J&J
Trial completion: Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 27, 2016
P2, N=30, Completed, Sponsor: Scios, Inc.
Active, not recruiting --> Completed No longer recruiting --> Completed
- |||| talmapimod (SCIO-469) / J&J
Trial completion: Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 27, 2016
P2, N=62, Completed, Sponsor: Scios, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- | bortezomib / Generic mfg.
Trial completion: Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Feb 27, 2016
P1, N=40, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P1, N=46, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||| Empliciti (elotuzumab) / AbbVie, BMS
Enrollment change, Combination therapy: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 26, 2016
P2, N=51, Active, not recruiting, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed N=40 --> 51
- | bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion: Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma (clinicaltrials.gov) - Feb 26, 2016
P3, N=440, Completed, Sponsor: King Faisal Specialist Hospital & Research Center
N=40 --> 51 Recruiting --> Completed
- | balixafortide (POL 6326) / Spexis
Trial completion, Enrollment change, Trial primary completion date, Metastases: Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 26, 2016
P1/2, N=38, Completed, Sponsor: Polyphor Ltd.
Recruiting --> Completed Recruiting --> Completed | N=80 --> 38 | Trial primary completion date: Dec 2016 --> Nov 2015
- |||| lenalidomide / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Trial primary completion date, Combination therapy: Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) (clinicaltrials.gov) - Feb 26, 2016
P1/2, N=82, Completed, Sponsor: UMC Utrecht
Recruiting --> Completed | N=80 --> 38 | Trial primary completion date: Dec 2016 --> Nov 2015 Recruiting --> Completed | Trial primary completion date: May 2015 --> Nov 2014
- leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Feb 24, 2016
P2, N=47, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Completed | Trial primary completion date: May 2015 --> Nov 2014 Trial primary completion date: Dec 2015 --> Oct 2014
- sotatercept (MK-7962) / BMS, Merck (MSD)
Trial primary completion date: A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 23, 2016
P2a, N=20, Recruiting, Sponsor: Rebecca Silbermann
Trial primary completion date: Dec 2015 --> Oct 2014 Trial primary completion date: Jan 2016 --> Jan 2017
- New trial: TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed. (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=130, Not yet recruiting, Sponsor: Institute of Liver and Biliary Sciences, India
- Folotyn (pralatrexate) / Aurobindo
Trial completion, Enrollment change, Combination therapy: Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM (clinicaltrials.gov) - Feb 22, 2016
P1, N=11, Completed, Sponsor: Stanford University
Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Completed | N=28 --> 11
- || azintuxizumab vedotin (ABBV-838) / AbbVie
Clinical: Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2016
P1, N=161, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed | N=28 --> 11 N=100 --> 161
- Enrollment open: UK-PK: National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=60, Recruiting, Sponsor: Hampshire Hospitals NHS Foundation Trust
N=100 --> 161 Not yet recruiting --> Recruiting
- ||||||| Trial completion, Enrollment change, Trial primary completion date: IGIV Study for Chronic ITP Patients Ages 3-70 (clinicaltrials.gov) - Feb 21, 2016
P3, N=58, Completed, Sponsor: Grifols Biologicals Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed | N=75 --> 58 | Trial primary completion date: Mar 2017 --> Mar 2012
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Enrollment open, Trial primary completion date: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Feb 21, 2016
P1, N=22, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Completed | N=75 --> 58 | Trial primary completion date: Mar 2017 --> Mar 2012 Suspended --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- Rituxan (rituximab) / Roche
Trial primary completion date: PLRG4: First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (clinicaltrials.gov) - Feb 18, 2016
P3, N=250, Active, not recruiting, Sponsor: Polish Lymphoma Research Group
Suspended --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: May 2015 --> Jun 2017
- Trial primary completion date: UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma (clinicaltrials.gov) - Feb 18, 2016
P2, N=20, Recruiting, Sponsor: University of Arkansas
Trial primary completion date: May 2015 --> Jun 2017 Trial primary completion date: Jan 2016 --> Jul 2016
- bortezomib / Generic mfg.
Trial primary completion date, Combination therapy: Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 17, 2016
P1, N=12, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jan 2016 --> Jul 2016 Trial primary completion date: Jan 2016 --> Apr 2016
- Targretin oral (bexarotene oral) / ReXceptor, efatutazone (CS-7017) / Daiichi Sankyo
Trial primary completion date: Phase I Study of CS-7017 and Bexarotene (clinicaltrials.gov) - Feb 17, 2016
P1, N=9, Terminated, Sponsor: Georgetown University
Trial primary completion date: Jan 2016 --> Apr 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- | Trial completion: Blood and Marrow Transplant Clinical Research Network (clinicaltrials.gov) - Feb 16, 2016
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed
- Signifor LAR (pasireotide long acting release) / Recordati
Trial initiation date, Trial primary completion date, Combination therapy: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2016
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Recruiting --> Completed Initiation date: Dec 2012 --> Dec 2011 | Trial primary completion date: Mar 2014 --> Feb 2012
- Trial completion: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Feb 12, 2016
P2/3, N=16, Completed, Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
Initiation date: Dec 2012 --> Dec 2011 | Trial primary completion date: Mar 2014 --> Feb 2012 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency (clinicaltrials.gov) - Feb 12, 2016
P1, N=7, Completed, Sponsor: ProMetic BioTherapeutics, Inc
Active, not recruiting --> Completed Recruiting --> Completed | N=12 --> 7 | Trial primary completion date: Apr 2016 --> Dec 2015